"Valsartan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.
| Descriptor ID |
D000068756
|
| MeSH Number(s) |
D03.383.129.617.850 D12.125.070.950.550 D12.125.142.930.500
|
| Concept/Terms |
Valsartan- Valsartan
- N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
|
Below are MeSH descriptors whose meaning is more general than "Valsartan".
Below are MeSH descriptors whose meaning is more specific than "Valsartan".
This graph shows the total number of publications written about "Valsartan" by people in this website by year, and whether "Valsartan" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 6 | 21 | 27 |
| 2018 | 4 | 22 | 26 |
| 2019 | 2 | 9 | 11 |
| 2020 | 1 | 3 | 4 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Valsartan" by people in Profiles.
-
The angiotensin II type 1 receptor blocker valsartan in the battle against COVID-19. Obesity (Silver Spring). 2021 09; 29(9):1423-1426.
-
Role of Hydrogen Bonds in Formation of Co-amorphous Valsartan/Nicotinamide Compositions of High Solubility and Durability with Anti-hypertension and Anti-COVID-19 Potential. Mol Pharm. 2021 05 03; 18(5):1970-1984.
-
Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. Med Hypotheses. 2021 Feb; 147:110486.
-
The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19. Int J Mol Sci. 2020 Nov 15; 21(22).
-
[Impact of the COVID-19 pandemic on the management of heart failure outpatient clinics. Lessons during the lockdown restrictions]. G Ital Cardiol (Rome). 2020 Oct; 21(10):750-756.
-
Sacubitril/valsartan in COVID-19 patients: the need for trials. Eur Heart J Cardiovasc Pharmacother. 2020 07 01; 6(4):253-254.
-
Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients. Eur Heart J Cardiovasc Pharmacother. 2020 07 01; 6(3):135-136.
-
Effect of angiotensin II blockers on the prognosis of COVID-19: a toxicological view. Eur J Clin Microbiol Infect Dis. 2020 Oct; 39(10):2001-2002.
-
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. JACC Heart Fail. 2020 10; 8(10):789-799.
-
Clinical experience with therapeutic dose of Low-Molecular-Weight Heparin. Infez Med. 2020 Jun 01; 28(suppl 1):118-121.